Annual report pursuant to Section 13 and 15(d)

Stockholders Equity (Tables)

v3.22.1
Stockholders Equity (Tables)
12 Months Ended
Dec. 31, 2021
Stockholders Equity (Tables) [Line Items]  
Schedule of outstanding warrants
Warrant   Issuance Date   Expiration
Date
  Exercise
Price
Per Share
    Number of
Shares of
Common Stock
Underlying
Warrants
 
Private Placement Warrants   IPO (December 13, 2018)   December 13, 2023     11.50       2,900,000  
Public Warrants   IPO (December 13, 2018)   October 28, 2024     11.50       3,500,000  
2021 Registered Direct Offering Warrants   SPA (July 28, 2021)   January 28, 2027     5.00       2,812,501  
                      9,212,501  

 

Schedule of black-scholes option-pricing model
    2021     2020  
             
Underlying value of Common Stock ($)     7.02       5.59-6.44  
Exercise price ($)     7.02       5.59-6.44  
Expected volatility (%)     85.0       85.0  
Expected terms of the option (years)     6.11       6.11  
Risk-free interest rate (%)     1.17       0.39-0.68  

Schedule of options granted to purchase common stock
    For year ended
December 31, 2021
 
    Number of
Options
    Weighted
average
exercise
price
    Aggregate
intrinsic
value
 
                   
Outstanding at the beginning of period     3,569,766     $ 3.12     $ 12,338  
Granted     985,530       7.02          
Forfeited     (386,508 )     4.60          
Exercised     (84,239 )   $ 1.55          
Outstanding at the end of period     4,084,549       3.95     $ 671  
Vested at end of period     2,486,381                  
Weighted average remaining contractual life – years as of December 31, 2021     6.82                  

 

    For year ended
December 31, 2020
 
    Number of
Options
    Weighted
average
exercise
price
    Aggregate
intrinsic
value
 
                   
Outstanding at the beginning of period     3,143,802     $ 1.61     $ 25,733  
Granted     925,700       6.17          
Forfeited     (108,110 )     4.66          
Exercised     (391,626 )   $ 0.79          
Outstanding at the end of period     3,569,766     $ 3.12     $ 12,338  
Vested at end of period     2,334,037                  
Weighted average remaining contractual life – years as of December 31, 2020     7.62                  

 

Schedule of share-based payment expenses
    Year ended
December 31,
 
    2021     2020  
             
Research and development expenses, net     1,770       1,815  
General and administrative     1,467       1,075  
      3,237       2,890  

 

Warrant [Member]  
Stockholders Equity (Tables) [Line Items]  
Schedule of outstanding warrants
Warrant   Issuance Date     Expiration
Date
  Exercise
Price
Per Share
 
    Number of
Shares of
Common Stock
Underlying
Warrants
 
 
Private Warrants issued to Yeda (see 1 below)   May 11, 2017   May 11, 2025    
(*
)    
   -
 
Private Warrants issued to scientific founders (see 2 below)   November 27, 2017        
-
      2,974  
                      2,974